Statement of Changes in Beneficial Ownership (4)
25 Januar 2022 - 10:38PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
| 1. Name
and Address of Reporting Person * Mattsson Jan |
2. Issuer Name and Ticker or Trading
Symbol ALBIREO PHARMA, INC. [ ALBO ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
Chief Scientific Officer |
|
(Last)
(First)
(Middle)
C/O ALBIREO PHARMA INC., 10 POST OFFICE SQUARE, SUITE
1000 |
3. Date of Earliest Transaction (MM/DD/YYYY)
1/24/2022
|
|
(Street)
BOSTON, MA 02109
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
Amount |
(A) or (D) |
Price |
|
Common Stock |
1/24/2022 |
|
S |
|
808 (1) |
D |
$24.8822 (2) |
58366 (3) |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Explanation of
Responses: |
| (1) |
Shares sold pursuant to a
Rule 10b5-1 arrangement established in October 2019 to satisfy tax
obligations arising out of the vesting of previously granted
restricted stock units. |
| (2) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $24.7811 to $24.97, inclusive.
The reporting person undertakes to provide to the Issuer, any
security holder of the Issuer, or the staff of the Securities and
Exchange Commission, on request, full information regarding the
number of shares sold at each separate price within the range set
forth above. |
| (3) |
Represents 32,641 shares of
common stock and 25,725 restricted stock units. |
Reporting
Owners
|
|
Reporting Owner Name / Address |
Relationships
|
|
Director |
10% Owner |
Officer |
Other |
Mattsson Jan
C/O ALBIREO PHARMA INC.
10 POST OFFICE SQUARE, SUITE 1000
BOSTON, MA 02109 |
|
|
Chief Scientific Officer |
|
Signatures
|
|
/s/ Jason Duncan,
Attorney-in-fact |
|
1/25/2022 |
| **Signature of Reporting
Person |
Date |
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Jul 2022 bis Aug 2022
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Aug 2021 bis Aug 2022
